We did not observe any significant modifications in CD4+ and macrophage populations after the treatments, whereas a higher count of CD8+ cells was observed after i.t. and p.t. IL-12 GET in B16-F10 melanoma, and after CaEP with p.t. IL-12 GET in 4T1 breast carcinoma (Figures 6, 7). This evidence concerns the gene CD8A and breast carcinoma.